TELA Bio (TELA)
Reinforced tissue matrices for hernia and soft-tissue reconstruction.
Something off on this page? Send us feedback.
Sells single-use OviTex and OviTex PRS reinforced tissue matrices to hospitals for hernia repair, abdominal-wall reconstruction, and plastic and reconstructive surgery. Revenue relies on the licensed Aroa platform, which is also the exclusive manufacturer and supplier for both core portfolios.
Combines ovine-derived extracellular matrix with embroidered polymer reinforcement in tissue matrices for surgical repair. The OviTex portfolio serves ventral, inguinal, and hiatal hernia repair and abdominal-wall reconstruction; OviTex PRS supports plastic and reconstructive surgery where soft-tissue weakness exists.
Sells mainly single-use implants to hospital accounts through a predominantly direct commercial organization in the United States and Europe, supplemented by distributors in selected European markets.
Relies on Aroa Biosurgery as exclusive contract manufacturer and supplier for both core portfolios. Aroa holds OviTex U.S. clearances, while TELA holds OviTex PRS clearances; that license relationship and ongoing regulatory compliance underpin nearly all product revenue.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Dec 1, 2025 | Loop Capital Markets | Target | Target: — | Target: $3 |
| Dec 1, 2025 | Lake Street | Reiterate | Rating: —Target: $8 | Target: $3 |
| Nov 14, 2025 | Piper Sandler | Reiterate | Rating: —Target: $8 | Target: $1.25 |
| Mar 21, 2025 | Piper Sandler | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $30.4M · Total debt $56.6M · Total assets $59.7M · Shareholders' equity −$15.9M
- Revenue
- $19.3M
- Operating income
- −$9.3M
- Net income
- −$11.3M
No dividends on record.
| Institutions | 57.51% | 25.75M shares | |
|---|---|---|---|
| 44 holders · as of Jun 30, 2026 | |||
| Insiders | 10.92% | 4.89M shares | |
| 20 holders · as of Sep 18, 2026 | |||
| Other | 31.57% | 14.13M shares | |
| remainder | |||
44.77M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Essex Woodlands Management, Inc.Institution | 17.23% | 7.71M | as of Jun 30, 2026 |
Nantahala Capital Management, LLCInstitution | 13.17% | 5.89M | as of Jun 30, 2026 |
Stonepine Capital Management, LLCInstitution | 5.95% | 2.66M | as of Jun 30, 2026 |
Lytton, Laurence W.Insider | 5.46% | 2.44M | filed May 15, 2026 |
Silverarc Capital Management, LLCInstitution | 4.77% | 2.14M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 17, 2026 | Joseph H. Capper | director | +25,000 | $1.22 |
| Sep 16, 2026 | Joseph H. Capper | director | +50,000 | $1.17 |
| Sep 15, 2026 | Joseph H. Capper | director | +50,000 | $1.06 |
| Sep 14, 2026 | Joseph H. Capper | director | +25,000 | $1.02 |
| Aug 17, 2026 | Heather C. Getz | director, officer: Chief Executive Officer | +12,500 | $0.6649 |
- BD
Hernia-mesh rival with Phasix and Ventralight ST.
- AbbVie
Biologic-matrix rival in abdominal-wall and reconstructive surgery.
- Medtronic
Large-scale hernia-mesh rival in inguinal and ventral repair.
- Integra LifeSciences
Reconstructive-matrix rival with SurgiMend and DuraSorb.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| TELA Bio | $1.44 | +2.13% | $63.1M | — | — | 0.8 | −4.5% |
| BD | $183.10 | +0.05% | $50.42B | 55.1 | 13.8 | 2.4 | −9.6% |
| AbbVie | $264.77 | −0.16% | $468.77B | 74.8 | 17.4 | 7.3 | +10.2% |
| Medtronic | $90.21 | −0.62% | $116.19B | 22.4 | 15.0 | 3.1 | +13.7% |
| Integra LifeSciences | $15.77 | −1.56% | $1.25B | — | 6.2 | 0.8 | +0.8% |
| Median | 55.1 | 14.4 | 2.8 | +5.5% |